Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Neoadjuvant Therapy in Esophageal Squamous Cell Carcinoma
NCT04568200Phase 2Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jun 2020
- Primary completion
- Dec 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Peking Union Medical College Hospital. Started Jun 2020; status: completed.
02
Drugs
durvalumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04568200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04568200.